Page last updated: 2024-10-20

pyrazinamide and Demyelinative Myelitis

pyrazinamide has been researched along with Demyelinative Myelitis in 1 studies

pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.

Research Excerpts

ExcerptRelevanceReference
"Incomplete transverse myelitis (ITM) of unknown origin is associated with high rates of morbidity and mortality."1.37Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study. ( Chen, X; Feng, Y; Guo, N; Huang, F; Lai, R; Liu, J; Sun, Q, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Feng, Y1
Guo, N1
Liu, J1
Chen, X1
Sun, Q1
Lai, R1
Huang, F1

Other Studies

1 other study available for pyrazinamide and Demyelinative Myelitis

ArticleYear
Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study.
    Clinical & developmental immunology, 2011, Volume: 2011

    Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Met

2011